1.96
-0.01 (-0.51%)
| Previous Close | 1.97 |
| Open | 1.99 |
| Volume | 28,650 |
| Avg. Volume (3M) | 66,780 |
| Market Cap | 696,168,640 |
| Price / Earnings (Forward) | 53.48 |
| Price / Sales | 0.830 |
| Price / Book | 0.880 |
| 52 Weeks Range |
| Profit Margin | -26.26% |
| Operating Margin (TTM) | -9.91% |
| Diluted EPS (TTM) | -0.690 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Total Debt/Equity (MRQ) | 52.48% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | 34.59 M |
| Levered Free Cash Flow (TTM) | -90.11 M |
| Return on Assets (TTM) | -2.42% |
| Return on Equity (TTM) | -20.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Evotec SE | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Institutions | 2.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Optiver Holding B.V. | 31 Mar 2026 | 283,576 |
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 31 Mar 2026 | 24,409 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |